Assenagon Asset Management
ADMA icon

Assenagon Asset Management’s ADMA Biologics ADMA Stock Holding History

Assenagon Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,050
Closed -$219K – 1163
2025
Q2 		$219K Sell
12,050
-387,872
-97% -$7.91M ﹤0.01% 1116
2025
Q1 		$7.93M Sell
399,922
-191,757
-32% -$3.32M 0.01% 463
2024
Q4 		$10.1M Sell
591,679
-2,882,776
-83% -$54.2M 0.02% 517
2024
Q3 		$69.5M Buy
3,474,455
+92,281
+3% +$1.44M 0.13% 141
2024
Q2 		$37.8M Buy
3,382,174
+35,707
+1% +$300K 0.08% 180
2024
Q1 		$22.1M Sell
3,346,467
-598,758
-15% -$3.27M 0.05% 259
2023
Q4 		$17.8M Sell
3,945,225
-1,088,946
-22% -$4.03M 0.05% 316
2023
Q3 		$18M Sell
5,034,171
-605,799
-11% -$2.33M 0.06% 269
2023
Q2 		$20.8M Sell
5,639,970
-1,025,051
-15% -$3.8M 0.07% 225
2023
Q1 		$22.1M Buy
6,665,021
+4,299,301
+182% +$14.9M 0.08% 221
2022
Q4 		$9.18M Buy
2,365,720
+1,297,973
+122% +$4M 0.03% 400
2022
Q3 		$2.6M Sell
1,067,747
-21,360
-2% -$51.2K 0.01% 639
2022
Q2 		$2.16M Buy
1,089,107
+585,707
+116% +$1.15M 0.01% 807
2022
Q1 		$921K Buy
503,400
+371,956
+283% +$580K ﹤0.01% 1075
2021
Q4 		$185K Buy
131,444
+49,899
+61% +$65.6K ﹤0.01% 1380
2021
Q3 		$92K Buy
81,545
+19,169
+31% +$26.9K ﹤0.01% 1262
2021
Q2 		$100K Sell
62,376
-14,811
-19% -$26.1K ﹤0.01% 1168
2021
Q1 		$136K Buy
+77,187
New +$177K ﹤0.01% 1165
2020
Q3 		– Sell
-412,534
Closed -$1.21M – 1101
2020
Q2 		$1.21M Buy
+412,534
New +$1.19M 0.01% 748

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.82B AUM 73.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Assenagon Asset Management's ADMA Position: Q3 2025 in Review

Assenagon Asset Management sold out of ADMA Biologics (ADMA) in Q3 2025, closing a stake of 12,050 shares — an estimated $219K sold.

Assenagon Asset Management first reported a position in ADMA in Q2 2020 and held it in 19 quarters. The position peaked at $69.5M in Q3 2024. 365 funds tracked by Wall St. Rank hold ADMA as of Q3 2025.

  • Assenagon Asset Management reported no remaining ADMA Biologics position as of Q3 2025 after selling out during the quarter.
  • Assenagon Asset Management sold 12,050 ADMA Biologics shares in Q3 2025, an estimated $219K.
  • Assenagon Asset Management first reported a position in ADMA Biologics in Q2 2020 and held it in 19 quarters.
  • Assenagon Asset Management's ADMA Biologics position peaked at $69.5M in Q3 2024.
  • 365 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2025.

Based on Assenagon Asset Management's 13F filing for Q3 2025, filed 7 Oct 2025.